Pfizer Faces Expanded Vaccine Lawsuits While Fair Value Narrative Sees 14.6% Upside

Simply Wall St··Read original
2▲1 ▼1Impact / 5
Summary · why it matters

Pfizer is facing expanded patent litigation from Arbutus Biopharma and Genevant Sciences over mRNA lipid nanoparticle technology, with new international cases adding legal and operational questions for its COVID-19 vaccine business. The most followed valuation narrative pegs Pfizer's fair value at about $29.19 per share versus a recent close of $24.94, suggesting the stock is materially discounted once future cash flows are adjusted using a 7.11% discount rate. This narrative assumes robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, will drive sustained long-term revenue and earnings growth. However, the outlook depends on Pfizer offsetting revenue headwinds and patent expiries, and on regulators not imposing tighter pricing rules that squeeze long-term margins. The stock showed a 1-day return of 0.77% and a 7-day return of 2.85%, but a 90-day decline of 6.94%, while the 1-year total shareholder return stands at 6.14%.

Impact on assets 2

Biotech & Genomic Medicine± Mixed · 2 stocks
Pfizer Inc
PFE
▼ NegativeRegulationrelevance

Pfizer faces expanded patent lawsuits over mRNA lipid nanoparticle technology, adding legal and operational risks to its COVID-19 vaccine business.

Arbutus Biopharma Corp
ABUS
▲ PositiveRegulationrelevance

Arbutus Biopharma and Genevant Sciences are expanding patent litigation against Pfizer, which could lead to licensing fees or damages for Arbutus.

Off-coverage companies 1

Genevant SciencesPrivate▲ Positive
Regulationrelevance

Genevant Sciences is co-plaintiff in expanded patent litigation against Pfizer, potentially benefiting from licensing fees or damages.

© 2026 MarketIVNews